Carr A - Search Results

1

Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes.

Zaunders J, Carr A, McNally L, Penny R, Cooper DA. Zaunders J, et al. Among authors: carr a. AIDS. 1995 Jun;9(6):561-6. doi: 10.1097/00002030-199506000-00005. AIDS. 1995. PMID: 7662193

2

Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.

Carr A, Tindall B, Penny R, Cooper DA. Carr A, et al. AIDS. 1992 Feb;6(2):165-71. doi: 10.1097/00002030-199202000-00004. AIDS. 1992. PMID: 1558714

3

Allergic manifestations of human immunodeficiency virus (HIV) infection.

Carr A, Cooper DA, Penny R. Carr A, et al. J Clin Immunol. 1991 Mar;11(2):55-64. doi: 10.1007/BF00917741. J Clin Immunol. 1991. PMID: 1676034

4

Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients.

Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Carr A, et al. AIDS. 1994 Mar;8(3):333-7. doi: 10.1097/00002030-199403000-00006. AIDS. 1994. PMID: 8031511

5

In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV.

Carr A, Tindall B, Penny R, Cooper DA. Carr A, et al. Clin Exp Immunol. 1993 Oct;94(1):21-5. doi: 10.1111/j.1365-2249.1993.tb05971.x. Clin Exp Immunol. 1993. PMID: 8403509 Free PMC article.

6

Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response.

Tindall B, Carr A, Goldstein D, Penny R, Cooper DA. Tindall B, et al. Among authors: carr a. AIDS. 1993 Jan;7(1):127-8. doi: 10.1097/00002030-199301000-00020. AIDS. 1993. PMID: 8442903 No abstract available.

7

Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients.

Carr A, Penny R, Cooper DA. Carr A, et al. AIDS. 1993 Jan;7(1):65-71. doi: 10.1097/00002030-199301000-00010. AIDS. 1993. PMID: 8442919

8

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.

Kelleher AD, Carr A, Zaunders J, Cooper DA. Kelleher AD, et al. Among authors: carr a. J Infect Dis. 1996 Feb;173(2):321-9. doi: 10.1093/infdis/173.2.321. J Infect Dis. 1996. PMID: 8568292 Clinical Trial.

9

Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group.

Imrie A, Carr A, Duncombe C, Finlayson R, Vizzard J, Law M, Kaldor J, Penny R, Cooper DA. Imrie A, et al. Among authors: carr a. J Infect Dis. 1996 Jul;174(1):195-8. doi: 10.1093/infdis/174.1.195. J Infect Dis. 1996. PMID: 8655994

10

A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.

Carr A, Vella S, de Jong MD, Sorice F, Imrie A, Boucher CA, Cooper DA. Carr A, et al. AIDS. 1996 Jun;10(6):635-41. doi: 10.1097/00002030-199606000-00009. AIDS. 1996. PMID: 8780818 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,547 results

Search Page

Filters